The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | HIMALAYA: outcomes by comorbidities with STRIDE in hepatocellular carcinoma
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the impact of cardiovascular and metabolic conditions on outcomes in the HIMALAYA trial (NCT03298451), which assessed single tremelimumab and regular interval durvalumab (STRIDE) versus sorafenib in hepatocellular carcinoma (HCC). Patients with hypertension and type 2 diabetes achieved similar overall survival benefits from STRIDE as those without, and higher long-term survival rates were observed. Safety profiles were consistent, underscoring the benefits of STRIDE in a diverse patient population. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
